Clinical Trial Update: Efficacy and Safety of Niraparib Combined With Oral Etoposide in Platinum Resistant/Refractory Recurrent Ovarian Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating niraparib plus oral etoposide in platinum-resistant/refractory recurrent ovarian cancer; efficacy and safety data are not yet specified…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Etoposide (oral) (etoposide)
• Niraparib (Niraparib)

Snippet

Sponsor: Peking Union Medical College Hospital | Conditions: Ovarian Cancer | Phase 2 | Status: UNKNOWN